{"id":"loprazolam","rwe":[{"pmid":"40750507","year":"2025","title":"A descriptive study of national trends in the dispensing of reimbursed hypnotics in France between 2012 and 2022.","finding":"","journal":"Sleep health","studyType":"Clinical Study"},{"pmid":"33988239","year":"2021","title":"Novel and Nonroutine Benzodiazepines and Suvorexant by LC-MS-MS.","finding":"","journal":"Journal of analytical toxicology","studyType":"Clinical Study"},{"pmid":"32306862","year":"2021","title":"Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes.","finding":"","journal":"Journal of biomolecular structure & dynamics","studyType":"Clinical Study"},{"pmid":"28094153","year":"2017","title":"Development and validation of a fast ionic liquid-based dispersive liquid-liquid microextraction procedure combined with LC-MS/MS analysis for the quantification of benzodiazepines and benzodiazepine-like hypnotics in whole blood.","finding":"","journal":"Forensic science international","studyType":"Clinical Study"},{"pmid":"25627407","year":"2015","title":"Detection of Benzodiazepines and z-Drugs in Hair Using an UHPLC-MS/MS Validated Method: Application to Workplace Drug Testing.","finding":"","journal":"Therapeutic drug monitoring","studyType":"Clinical Study"}],"tags":[{"label":"loprazolam","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"GABA-A receptor alpha-1/beta-3/gamma-2","category":"target"},{"label":"GABRA1","category":"gene"},{"label":"GABRB3","category":"gene"},{"label":"GABRG2","category":"gene"},{"label":"N05CD11","category":"atc"},{"label":"Active","category":"status"},{"label":"Insomnia","category":"indication"}],"phase":"marketed","safety":{"safetySignals":[{"llr":220.016,"date":"","count":73,"signal":"Coma","source":"DrugCentral FAERS","actionTaken":"Reported 73 times (LLR=220)"},{"llr":105.297,"date":"","count":27,"signal":"Miosis","source":"DrugCentral FAERS","actionTaken":"Reported 27 times (LLR=105)"},{"llr":80.502,"date":"","count":48,"signal":"Somnolence","source":"DrugCentral FAERS","actionTaken":"Reported 48 times (LLR=81)"},{"llr":69.529,"date":"","count":16,"signal":"Bradypnoea","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=70)"},{"llr":68.465,"date":"","count":11,"signal":"Pyramidal tract syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=68)"},{"llr":67.662,"date":"","count":51,"signal":"Toxicity to various agents","source":"DrugCentral FAERS","actionTaken":"Reported 51 times (LLR=68)"},{"llr":58.124,"date":"","count":22,"signal":"Hepatocellular injury","source":"DrugCentral FAERS","actionTaken":"Reported 22 times (LLR=58)"},{"llr":52.486,"date":"","count":26,"signal":"Rhabdomyolysis","source":"DrugCentral FAERS","actionTaken":"Reported 26 times (LLR=52)"},{"llr":43.569,"date":"","count":14,"signal":"Poisoning deliberate","source":"DrugCentral FAERS","actionTaken":"Reported 14 times (LLR=44)"},{"llr":40.724,"date":"","count":12,"signal":"Bundle branch block right","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=41)"},{"llr":38.237,"date":"","count":9,"signal":"Idiopathic intracranial hypertension","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=38)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=LOPRAZOLAM","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:55:47.150621+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:55:52.847959+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LOPRAZOLAM","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:55:53.241808+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2107448/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:55:53.953407+00:00"}},"allNames":["loprazolam mesylate","loprazolam","loprazolam mesilate"],"offLabel":[],"synonyms":["loprazolam mesylate","loprazolam","loprazolam mesilate"],"timeline":[{"date":"1983-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"approvals":[{"date":"1983-01-01","orphan":false,"company":"","regulator":"YEAR INTRODUCED"}],"ecosystem":[{"indication":"Insomnia","otherDrugs":[{"name":"amobarbital","slug":"amobarbital","company":""},{"name":"choline","slug":"choline","company":""},{"name":"daridorexant","slug":"daridorexant","company":"Idorsia Pharmaceuticals Ltd"},{"name":"diphenhydramine","slug":"diphenhydramine","company":"Mcneil Cons"}],"globalPrevalence":750000000}],"mechanism":{"target":"GABA-A receptor alpha-1/beta-3/gamma-2","targets":[{"gene":"GABRA1","source":"DrugCentral","target":"GABA-A receptor alpha-1/beta-3/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit alpha-1"},{"gene":"GABRB3","source":"DrugCentral","target":"GABA-A receptor alpha-1/beta-3/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit beta-3"},{"gene":"GABRG2","source":"DrugCentral","target":"GABA-A receptor alpha-1/beta-3/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit gamma-2"},{"gene":"GABRA2","source":"DrugCentral","target":"GABA-A receptor alpha-2/beta-3/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit alpha-2"},{"gene":"GABRA3","source":"DrugCentral","target":"GABA-A receptor alpha-3/beta-3/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit alpha-3"},{"gene":"GABRA5","source":"DrugCentral","target":"GABA-A receptor alpha-5/beta-3/gamma-2","protein":"Gamma-aminobutyric acid receptor subunit alpha-5"}],"modality":"Small Molecule","drugClass":"loprazolam","explanation":"","oneSentence":"","technicalDetail":"Loprazolam acts as a positive allosteric modulator of the GABA-A receptor, specifically targeting the alpha-1/beta-3/gamma-2 subunit, which enhances the receptor's sensitivity to GABA and increases the frequency of chloride ion influx, leading to hyperpolarization and sedative effects."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1602","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LOPRAZOLAM","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T14:09:11.244527","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:55:55.536730+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"flurazepam","drugSlug":"flurazepam","fdaApproval":"1970-04-07","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"estazolam","drugSlug":"estazolam","fdaApproval":"1990-12-26","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"triazolam","drugSlug":"triazolam","fdaApproval":"1982-11-15","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"temazepam","drugSlug":"temazepam","fdaApproval":"1981-02-27","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"midazolam","drugSlug":"midazolam","fdaApproval":"1985-12-20","patentExpiry":"Jun 20, 2038","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"quazepam","drugSlug":"quazepam","fdaApproval":"1985-12-27","patentExpiry":"Jun 3, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"remimazolam","drugSlug":"remimazolam","fdaApproval":"2020-07-02","patentExpiry":"Nov 7, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"loprazolam","indications":{"approved":[{"name":"Insomnia","source":"DrugCentral","snomedId":193462001,"regulator":"FDA","usPrevalence":70000000,"globalPrevalence":750000000,"prevalenceMethod":"curated","prevalenceSource":"Sleep Medicine Reviews, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"flurazepam","brandName":"flurazepam","genericName":"flurazepam","approvalYear":"1970","relationship":"same-class"},{"drugId":"estazolam","brandName":"estazolam","genericName":"estazolam","approvalYear":"1990","relationship":"same-class"},{"drugId":"triazolam","brandName":"triazolam","genericName":"triazolam","approvalYear":"1982","relationship":"same-class"},{"drugId":"temazepam","brandName":"temazepam","genericName":"temazepam","approvalYear":"1981","relationship":"same-class"},{"drugId":"midazolam","brandName":"midazolam","genericName":"midazolam","approvalYear":"1985","relationship":"same-class"},{"drugId":"quazepam","brandName":"quazepam","genericName":"quazepam","approvalYear":"1985","relationship":"same-class"},{"drugId":"remimazolam","brandName":"remimazolam","genericName":"remimazolam","approvalYear":"2020","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"004097","UNII":"759N8462G8","CHEBI":"CHEBI:135754","INN_ID":"4884","RXNORM":"235846","UMLSCUI":"C0077013","chemblId":"CHEMBL2107448","ChEMBL_ID":"CHEMBL2107448","KEGG_DRUG":"D07326","DRUGBANK_ID":"DB13643","PUBCHEM_CID":"3033860","SNOMEDCT_US":"321119005","SECONDARY_CAS_RN":"70111-54-5"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":79,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N05CD11","allCodes":["N05CD11"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Oct","pmid":"40750507","title":"A descriptive study of national trends in the dispensing of reimbursed hypnotics in France between 2012 and 2022.","journal":"Sleep health"},{"date":"2021 May 14","pmid":"33988239","title":"Novel and Nonroutine Benzodiazepines and Suvorexant by LC-MS-MS.","journal":"Journal of analytical toxicology"},{"date":"2021 May","pmid":"32306862","title":"Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes.","journal":"Journal of biomolecular structure & dynamics"},{"date":"2017 May","pmid":"28094153","title":"Development and validation of a fast ionic liquid-based dispersive liquid-liquid microextraction procedure combined with LC-MS/MS analysis for the quantification of benzodiazepines and benzodiazepine-like hypnotics in whole blood.","journal":"Forensic science international"},{"date":"2015 Oct","pmid":"25627407","title":"Detection of Benzodiazepines and z-Drugs in Hair Using an UHPLC-MS/MS Validated Method: Application to Workplace Drug Testing.","journal":"Therapeutic drug monitoring"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"LOPRAZOLAM","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"YEAR INTRODUCED","status":"approved","approval_date":"1983-01-01T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:55:55.536730+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}